Affordable Access

deepdyve-link
Publisher Website

Long-term outcomes of systemic corticosteroid-sparing immunomodulatory therapy for Birdshot Retinochoroidopathy.

Authors
  • You, Caiyun1, 2, 3
  • Lasave, Andres F1, 2, 4
  • Kubaisi, Buraa1, 2
  • Syeda, Sarah1, 2
  • Ma, Lina1, 2
  • Wai, Kelvin Cheng Kah1, 2, 5
  • Diaz, Mikhail Hernandez1, 2
  • Walsh, Marisa1, 2
  • Stephenson, Andrew1, 2
  • Montieth, Alyssa1, 2
  • Foster, C Stephen1, 2, 6
  • 1 Massachusetts Eye Research and Surgery Institution (MERSI) , Waltham , Massachusetts , USA.
  • 2 Ocular Immunology and Uveitis Foundation , Weston , Massachusetts , USA.
  • 3 Department of Ophthalmology, Tianjin Medical University General Hospital , Tianjin , China. , (China)
  • 4 Retina and Vitreous Department, Clinica Privada de Ojos, Mar del Plata , Buenos Aires , Argentina. , (Argentina)
  • 5 School of Medicine, University of Glasgow , Glasgow , United Kingdom. , (United Kingdom)
  • 6 Department of Ophthalmology, Harvard Medical School , Boston , Massachusetts , USA.
Type
Published Article
Journal
Ocular Immunology and Inflammation
Publisher
Informa UK (Taylor & Francis)
Publication Date
Sep 30, 2019
Pages
1–9
Identifiers
DOI: 10.1080/09273948.2019.1641610
PMID: 31567006
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Purpose: To report the visual prognosis, electroretinography (ERG) and perimetry outcomes of systemic corticosteroid-sparing immunomodulatory treatment (IMT) for birdshot retinochoroidopathy (BSRC). Methods: Retrospective non-comparative case series of 132 patients (264 eyes) with BSRC treated with IMT from Massachusetts Eye Research and Surgery Institution. Results: The average follow-up time was 60.1 months. After one year on IMT, 39.4% showed no clinically active inflammation. After 5 years of IMT, 78.0% had no signs of clinical inflammation. No significant differences were observed on best-corrected visual acuity (BCVA), ERG parameters, and perimetry parameters between baseline and subsequent visits on IMT. Conclusion: Long-term systemic corticosteroid-sparing IMT was associated with a low rate of BSRC disease exacerbation. While differences were seen on testing parameters, they were not consistent trends and difference were attributed to variability of testing or fluctuation of inflammation that may be expected in the course of the disease.

Report this publication

Statistics

Seen <100 times